drugset / Trial / NCT00661531

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

NCT00661531

Phase 2 Terminated 11 enrolled Georgetown University
NaSingle-groupOpen-labelTreatment

Summary

This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.

Timeline

Start
2008-04
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg
Subject Estradiol Other / unclassified 10 mg

Indications